Inolaxol: Uses, Dosage & Side Effects
A combination bulk-forming and stimulant laxative containing sterculia and frangula bark for the relief of constipation
Inolaxol is an over-the-counter combination laxative available as granules for the treatment of constipation. It contains two complementary active ingredients: sterculia (also known as karaya gum), a natural bulk-forming agent that absorbs water and increases stool volume, and frangula bark, a mild herbal stimulant laxative that promotes colonic motility. By combining both mechanisms, Inolaxol softens stools and gently stimulates the bowel, making it effective for occasional constipation in adults and adolescents. The granules must always be taken with a full glass of water to ensure safe passage through the gastrointestinal tract.
Quick Facts: Inolaxol
Key Takeaways
- Inolaxol combines two complementary laxative mechanisms: sterculia (bulk-forming) adds volume and softness to stools, while frangula bark (mild stimulant) promotes colonic motility for more complete bowel evacuation.
- The granules must always be taken with a full glass of water (at least 200 mL) to prevent swelling in the oesophagus or intestinal obstruction – never take Inolaxol dry or immediately before lying down.
- Effects typically begin within 8 to 24 hours, making it suitable for overnight relief when taken in the evening with adequate fluid intake.
- Inolaxol is available without prescription (OTC) and is generally well tolerated, with flatulence and abdominal bloating being the most commonly reported side effects during the first days of use.
- The stimulant component (frangula) should not be used continuously for more than one to two weeks without medical advice, as prolonged use may lead to electrolyte imbalance or reduced natural bowel function.
What Is Inolaxol and What Is It Used For?
Inolaxol is a well-established over-the-counter laxative that has been used for decades in clinical practice for the management of constipation. It belongs to a category of combination laxatives that harness two distinct pharmacological mechanisms to provide effective and gentle relief from constipation. The product is formulated as granules designed for oral administration with water, and its dual-action approach makes it particularly useful for patients who require both increased stool volume and mild stimulation of intestinal transit.
The first active ingredient, sterculia (also known as karaya gum or Indian tragacanth), is a natural polysaccharide derived from the exudate of Sterculia urens trees native to India and Southeast Asia. Sterculia is classified as a bulk-forming laxative. When ingested with adequate fluid, it absorbs water in the gastrointestinal tract and swells to form a soft, bulky gel that can expand up to 60 times its dry volume. This hydrated mass increases the volume of intestinal contents, which stretches the intestinal wall and triggers the peristaltic reflex – the natural wave-like contractions that propel contents through the bowel. The result is a softer, larger stool that is easier to pass. Unlike many osmotic or stimulant laxatives, bulk-forming agents work by mimicking the natural mechanism of a high-fibre diet, making them among the gentlest approaches to constipation management.
The second active ingredient, frangula bark (from Rhamnus frangula, also known as alder buckthorn), is a traditional herbal stimulant laxative that has been used in European and Asian medicine for centuries. Frangula bark contains anthraquinone glycosides, principally glucofrangulin A and glucofrangulin B, as well as frangulin A and frangulin B. These compounds are pharmacologically inactive prodrugs that pass through the upper gastrointestinal tract largely unabsorbed. Upon reaching the large intestine, they are hydrolysed by bacterial enzymes (beta-glucosidases) produced by the resident colonic microbiota into their active aglycone forms, primarily frangula-emodin. These active metabolites exert two key pharmacological effects on the colonic mucosa: first, they stimulate the submucosal nerve plexus (Auerbach’s plexus and Meissner’s plexus) to increase propulsive colonic motility; second, they inhibit water and electrolyte reabsorption from the colonic lumen while simultaneously promoting secretion of water and electrolytes into the intestinal lumen. The net effect is an accumulation of fluid in the colon, softening of the stool, and enhanced colonic contractions that facilitate bowel evacuation.
The combination of sterculia and frangula in Inolaxol is pharmacologically rational because the two components address constipation through complementary mechanisms. Sterculia provides the mechanical stimulus of increased stool bulk (similar to dietary fibre), while frangula provides the chemical stimulus of enhanced colonic secretion and motility. This dual approach is particularly beneficial for patients whose constipation involves both insufficient stool volume and sluggish colonic transit, which is common in many functional constipation presentations.
Constipation is one of the most prevalent gastrointestinal complaints worldwide, affecting an estimated 10–15% of the global adult population according to the World Gastroenterology Organisation (WGO). It is characterised by infrequent bowel movements (typically fewer than three per week), hard or lumpy stools, straining during defecation, a sensation of incomplete evacuation, or a sensation of anorectal obstruction. Constipation can significantly impair quality of life and is associated with increased healthcare utilisation and costs. While lifestyle modifications (increased dietary fibre, adequate hydration, and regular physical activity) form the foundation of constipation management, many patients require pharmacological assistance, particularly during acute episodes or when lifestyle changes alone are insufficient.
Inolaxol is indicated for the short-term symptomatic relief of occasional constipation in adults and adolescents over 12 years of age. It is particularly well-suited for patients who benefit from a combination approach and for those who find pure bulk-forming agents insufficiently effective on their own. The granule formulation offers convenience, as it can be taken directly with water or sprinkled onto food such as yoghurt, although it must always be followed by adequate fluid intake to ensure safe and effective passage through the gastrointestinal tract.
While Inolaxol is suitable for self-treatment of occasional constipation, you should consult a doctor if: constipation is a new and persistent problem (lasting more than two weeks), you notice blood in your stool, you experience unexplained weight loss, you have severe or worsening abdominal pain, or your normal bowel habit has changed significantly without an obvious cause. These symptoms may indicate an underlying condition that requires medical evaluation.
What Should You Know Before Taking Inolaxol?
Contraindications
Inolaxol must not be used in several clinical situations where the introduction of a bulk-forming or stimulant laxative could be harmful. The most critical contraindication is intestinal obstruction (bowel blockage), whether partial or complete. In an obstructed bowel, the swelling action of sterculia could worsen the obstruction, potentially leading to perforation or ischaemia, both of which are surgical emergencies. Similarly, Inolaxol is contraindicated in patients with faecal impaction, a condition where hardened stool is lodged in the rectum or colon and cannot be passed. In faecal impaction, a bulk-forming laxative would add volume proximal to the impaction, exacerbating the problem rather than resolving it; manual or enema-based disimpaction is required first.
Inolaxol is also contraindicated in patients with acute inflammatory bowel disease, including acute flares of Crohn’s disease or ulcerative colitis, and in patients with acute abdominal conditions such as appendicitis, peritonitis, or undiagnosed abdominal pain. Stimulant laxatives can increase intestinal motility and potentially exacerbate inflammation, bleeding, or perforation risk in these conditions. Patients with severe dehydration should not use Inolaxol, as the bulk-forming component requires adequate hydration to function safely.
Additionally, Inolaxol should not be used by individuals who have difficulty swallowing (dysphagia) or known oesophageal strictures, as the granules may swell before reaching the stomach, creating a risk of oesophageal obstruction. Patients with a known hypersensitivity to sterculia, frangula bark, or any excipient in the formulation should avoid the product.
Warnings and Precautions
Inolaxol granules must always be taken with at least a full glass of water (200–250 mL). Taking the granules without sufficient fluid can cause the sterculia to swell in the oesophagus or upper gastrointestinal tract, potentially leading to choking or intestinal obstruction. Remain upright for at least 30 minutes after taking the dose. Never take Inolaxol immediately before going to bed.
Several important precautions should be observed when using Inolaxol:
- Duration of use: Inolaxol should generally be used for no more than one to two weeks without medical supervision. The stimulant laxative component (frangula bark) can, with prolonged use, lead to electrolyte disturbances (particularly hypokalaemia – low potassium), fluid imbalance, and a condition known as “cathartic colon” where the bowel becomes dependent on stimulant laxatives and loses its natural ability to contract effectively. If constipation persists beyond two weeks, medical evaluation is recommended.
- Electrolyte monitoring: Patients who are already taking medications that affect electrolyte balance (such as diuretics or corticosteroids) or who have conditions that predispose them to electrolyte abnormalities (such as renal impairment) should use Inolaxol with caution and under medical supervision. Chronic hypokalaemia can affect cardiac function and may be particularly dangerous in patients taking cardiac glycosides such as digoxin.
- Diabetes: Some formulations of Inolaxol may contain sugars or sweeteners. Patients with diabetes should check the product labelling for sugar content and adjust their dietary intake accordingly. The carbohydrate content of the granules may need to be taken into account in meal planning.
- Elderly patients: Older adults are at increased risk of dehydration and electrolyte imbalance. Adequate fluid intake is particularly important in this population, and careful monitoring is advised if Inolaxol is used for more than a few days.
Pregnancy and Breastfeeding
Constipation is extremely common during pregnancy, affecting up to 40% of pregnant women, primarily due to the effects of progesterone on intestinal smooth muscle and the physical compression of the bowel by the growing uterus. However, the choice of laxative during pregnancy requires careful consideration.
The bulk-forming component of Inolaxol (sterculia) is generally considered safe during pregnancy, as it acts locally within the gastrointestinal tract, is not systemically absorbed, and works by a purely mechanical mechanism similar to dietary fibre. However, the stimulant laxative component (frangula bark) contains anthraquinone glycosides, and there are theoretical concerns about their safety in pregnancy. While there is no strong evidence of teratogenicity (birth defects) with anthraquinone laxatives at therapeutic doses, some preclinical studies have suggested that high doses of anthraquinones may stimulate uterine smooth muscle contractions. As a precaution, most clinical guidelines recommend avoiding stimulant laxatives during pregnancy, particularly during the first trimester, unless specifically advised by a healthcare provider.
Pregnant women experiencing constipation should discuss their options with their doctor or midwife. First-line treatments during pregnancy typically include lifestyle modifications (increased fibre and fluid intake, physical activity) and, if pharmacological treatment is needed, pure bulk-forming laxatives (such as ispaghula husk or sterculia alone) or osmotic laxatives (such as lactulose or macrogol), which are generally preferred over stimulant-containing products.
Small amounts of anthraquinone metabolites may be excreted in breast milk, although the clinical significance of this is considered minimal. Breastfeeding mothers should consult their healthcare provider before using Inolaxol and consider whether a non-stimulant alternative may be more appropriate.
Children and Adolescents
Inolaxol is generally not recommended for children under 12 years of age without specific medical advice. Constipation in young children is common and often related to dietary habits, toilet training issues, or withholding behaviour. Management of childhood constipation typically follows specific paediatric guidelines, with osmotic laxatives (such as macrogol-based products) being the preferred first-line pharmacological treatment. If a healthcare provider recommends Inolaxol for an adolescent (12 years and older), the standard adult dosage guidance should be followed, with particular attention to ensuring adequate fluid intake.
How Does Inolaxol Interact with Other Drugs?
While Inolaxol is an over-the-counter product and is generally considered safe for short-term use, there are several important drug interactions that patients and healthcare providers should be aware of. These interactions primarily relate to two mechanisms: the potential for the bulk-forming component to interfere with the absorption of other oral medications, and the risk of electrolyte disturbances (particularly hypokalaemia) caused by the stimulant laxative component with prolonged use.
Clinically Significant Interactions
| Drug / Drug Class | Interaction | Clinical Significance | Management |
|---|---|---|---|
| Cardiac glycosides (digoxin) | Hypokalaemia from chronic frangula use potentiates digoxin toxicity | High | Monitor potassium levels; avoid prolonged use |
| Antiarrhythmic drugs | Hypokalaemia may increase risk of cardiac arrhythmias | High | Monitor electrolytes; limit duration of laxative use |
| Thiazide & loop diuretics | Additive potassium depletion from both agents | Moderate | Monitor potassium; ensure adequate dietary potassium |
| Corticosteroids | Corticosteroids increase renal potassium excretion, compounding laxative-induced loss | Moderate | Avoid prolonged concurrent use; monitor electrolytes |
| Oral medications (general) | Bulk-forming sterculia may physically trap or delay absorption of co-administered oral drugs | Low to Moderate | Take other medications at least 1 hour before or 2 hours after Inolaxol |
| Anticoagulants (warfarin) | Altered absorption possible; diarrhoea may affect vitamin K absorption and INR | Low to Moderate | Monitor INR more frequently when starting or stopping Inolaxol |
Additional Considerations
The bulk-forming action of sterculia can create a viscous gel matrix in the gastrointestinal tract that may physically delay or reduce the absorption of other oral medications taken at the same time. This is a class effect shared by all bulk-forming laxatives and dietary fibre supplements. To minimise this risk, patients should take their regular oral medications at least one hour before or two hours after taking Inolaxol. This is particularly important for medications with a narrow therapeutic index, such as levothyroxine, lithium, antiepileptic drugs, and oral contraceptives.
The stimulant laxative component (frangula) does not undergo significant hepatic metabolism via cytochrome P450 enzymes, as its active metabolites are formed by bacterial enzymatic hydrolysis in the colon. Therefore, traditional pharmacokinetic drug-drug interactions mediated by CYP enzyme inhibition or induction are not expected. However, concurrent use of other laxatives (either prescription or over-the-counter) may produce additive effects and increase the risk of diarrhoea, dehydration, and electrolyte disturbance.
Patients taking potassium-sparing diuretics (spironolactone, amiloride, triamterene) or ACE inhibitors / ARBs may have some protective effect against hypokalaemia from laxative use, but this should not be relied upon as a substitute for limiting the duration of stimulant laxative therapy.
What Is the Correct Dosage of Inolaxol?
The correct dosage of Inolaxol depends on the specific product formulation available in your country, as sachet sizes and granule concentrations may vary between manufacturers and markets. Always follow the dosage instructions on the product packaging or as directed by your pharmacist or doctor. The following provides general guidance based on standard formulations.
Adults and Adolescents (over 12 years)
Standard Adult Dose
Take 1–2 sachets (approximately 5–10 g of granules) once or twice daily, preferably in the evening and/or morning. Swallow the granules with a full glass of water (at least 200–250 mL). The granules may also be mixed with soft food such as yoghurt, but must always be followed by adequate water intake. The dose should be adjusted individually based on the response achieved, starting with the lowest effective dose.
It is important to establish a consistent routine when using Inolaxol. Many patients find it most effective when taken in the evening, as the onset of action (8–24 hours) typically results in a morning bowel movement. Some patients may require a morning dose as well, particularly during the initial days of treatment. Once regular bowel habits are established, the dose should be gradually reduced to the minimum required to maintain regularity, and the product should be discontinued when no longer needed.
Children
Children Under 12 Years
Inolaxol is generally not recommended for children under 12 years of age. Constipation in younger children should be managed according to paediatric guidelines, typically with osmotic laxatives such as macrogol-based products as first-line treatment. If a healthcare provider specifically recommends Inolaxol for a child, follow their dosage instructions exactly.
Elderly Patients
Elderly Dose
Elderly patients should use the standard adult dose but should pay particular attention to maintaining adequate fluid intake throughout the day (at least 1.5–2 litres daily). Start with the lower end of the dosage range (1 sachet once daily) and increase only if needed. Elderly patients are at higher risk of dehydration and electrolyte imbalance, so the duration of treatment should be kept as short as possible and potassium levels should be monitored if use extends beyond one week.
Missed Dose
If you forget to take a dose of Inolaxol, simply take your next dose at the usual time. Do not take a double dose to make up for the missed one. Inolaxol is used for symptomatic relief rather than as a continuous treatment, so a single missed dose is unlikely to have any significant clinical consequence. If you are using Inolaxol on a regular short-term schedule prescribed by your doctor, try to maintain consistency but do not compensate by doubling doses.
Overdose
Taking significantly more than the recommended dose of Inolaxol may cause pronounced diarrhoea, abdominal cramps, nausea, and vomiting. The primary risks of overdose relate to fluid and electrolyte loss, particularly potassium depletion (hypokalaemia) and dehydration. Severe dehydration can cause dizziness, weakness, confusion, reduced urine output, and in extreme cases, cardiovascular compromise.
An overdose of the bulk-forming component (sterculia) also carries a risk of gastrointestinal obstruction, particularly if insufficient fluid was consumed. If you suspect an overdose or develop severe abdominal pain, persistent vomiting, bloody diarrhoea, or signs of dehydration (dry mouth, dark urine, dizziness), seek medical attention immediately. Treatment of overdose is supportive: replacement of fluids and electrolytes, monitoring of serum potassium and renal function, and management of any obstructive complications if they occur.
Always take Inolaxol with at least a full glass of water. Never take the granules dry. Remain upright for at least 30 minutes after each dose. Do not exceed the recommended dose. Do not use for more than two weeks without consulting your doctor.
What Are the Side Effects of Inolaxol?
Like all medicines, Inolaxol can cause side effects, although not everyone experiences them. Most side effects are mild, gastrointestinal in nature, and tend to improve after the first few days of use as the bowel adapts to the increased fibre load. The side effects listed below are categorised by their estimated frequency according to standard medical conventions.
Common
- Flatulence (intestinal gas) – particularly during the first days of treatment
- Abdominal bloating and distension
- Mild abdominal discomfort or cramping
- Increased frequency of bowel movements
- Loose stools (if dose is too high)
Uncommon
- Nausea
- Abdominal pain
- Diarrhoea (particularly with higher doses or prolonged use)
- Mild skin rash or itching (allergic reaction to plant-derived ingredients)
Rare
- Oesophageal obstruction (if taken without adequate water)
- Intestinal obstruction (if taken without adequate water or in patients with pre-existing narrowing)
- Allergic reactions (urticaria, angioedema)
- Electrolyte disturbances (hypokalaemia) with prolonged use of the frangula component
Not Known
- Melanosis coli (harmless dark pigmentation of the colonic mucosa with chronic anthraquinone use)
- Dependency on stimulant laxatives with prolonged use (cathartic colon)
- Protein-losing enteropathy (extremely rare, with chronic high-dose use)
The gastrointestinal side effects of flatulence and bloating are particularly common during the first few days of treatment and are a direct consequence of the bulk-forming mechanism. As sterculia absorbs water and expands in the intestinal lumen, it is partially fermented by colonic bacteria, producing gas. This effect diminishes significantly over the course of a few days as the gut microbiota adapts to the increased substrate. Starting with a lower dose and gradually increasing it over several days can help minimise these initial symptoms.
The risk of oesophageal or intestinal obstruction is the most clinically serious potential adverse event, but it is preventable through proper administration technique. The granules must always be taken with a full glass of water, the patient should remain upright, and the product should never be taken by patients with oesophageal strictures or swallowing difficulties.
With prolonged use (beyond two weeks), the frangula component may cause changes in electrolyte balance, particularly potassium depletion. Chronic hypokalaemia can manifest as muscle weakness, fatigue, constipation (paradoxically worsening the original problem), cardiac arrhythmias, and in severe cases, paralytic ileus. Additionally, long-term use of anthraquinone stimulant laxatives may cause melanosis coli, a benign and reversible brownish-black discolouration of the colonic mucosa that is detectable on colonoscopy. Melanosis coli itself is harmless and resolves within months of discontinuing the stimulant laxative, but its presence signals chronic laxative use that should be re-evaluated.
Contact your doctor or seek emergency medical care if you experience: severe abdominal pain, vomiting, choking or difficulty swallowing after taking the granules, blood in your stool, symptoms of a severe allergic reaction (difficulty breathing, swelling of face/lips/tongue), or signs of significant dehydration (persistent dizziness, very dark urine, rapid heartbeat).
How Should You Store Inolaxol?
Proper storage is essential to maintain the efficacy and safety of Inolaxol. The sterculia component is particularly sensitive to moisture because of its powerful water-absorbing properties – the same property that makes it effective as a laxative also means that exposure to ambient humidity can cause premature swelling, clumping, or degradation of the granules within the packaging.
Store Inolaxol at room temperature, generally below 25°C (77°F). Avoid storing the product in warm or humid environments such as bathrooms, kitchens near the stove, or in direct sunlight. The product should be kept in its original packaging (sachet, container, or blister) until the time of use, as the packaging is designed to protect the granules from moisture exposure. Once a sachet or container is opened, the contents should be used promptly and not stored for extended periods in an open state.
Keep Inolaxol out of the reach and sight of children. While the product is generally low in toxicity, accidental ingestion of a large quantity of granules by a child, particularly without adequate water, could potentially cause gastrointestinal obstruction.
Do not use Inolaxol after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month. Expired laxative granules may have reduced efficacy and the integrity of the active ingredients, particularly the anthraquinone glycosides in frangula bark, may have deteriorated. Dispose of expired or unused medication according to your local pharmaceutical waste disposal guidelines – do not flush medicines down the toilet or discard them in household waste unless specifically instructed to do so.
What Does Inolaxol Contain?
Active Ingredients
Sterculia (Karaya gum) is a complex, branched acidic polysaccharide obtained from the dried exudate of Sterculia urens Roxburgh and other species of the Sterculia genus (family Sterculiaceae). Karaya gum has been used for centuries in food and pharmaceutical applications due to its remarkable ability to absorb water and form a viscous, bulky gel. In Inolaxol, sterculia serves as the primary bulk-forming component. Chemically, it is composed of galactose, rhamnose, and galacturonic acid residues, with acetyl groups that contribute to its swelling behaviour. Sterculia is not significantly absorbed systemically and acts entirely within the gastrointestinal lumen.
Frangula bark (Rhamni frangulae cortex) is obtained from Rhamnus frangula L. (syn. Frangula alnus Mill.), also known as alder buckthorn, a shrub or small tree native to Europe, western Asia, and northern Africa. The bark must be aged for at least one year or heat-treated before pharmaceutical use, as fresh bark contains excessively irritant anthrones that can cause severe vomiting and bloody diarrhoea. Properly prepared frangula bark contains a standardised content of glucofrangulin A (the primary active glycoside) along with glucofrangulin B, frangulin A, frangulin B, and their aglycone frangula-emodin. These compounds are classified as anthraquinone glycosides and are responsible for the stimulant laxative effect of the bark.
Inactive Ingredients (Excipients)
The specific excipients in Inolaxol granules may vary slightly between different manufacturers and country-specific formulations. Typical inactive ingredients in sterculia-frangula granule preparations may include:
- Sucrose or other sweeteners – to improve palatability of the granules
- Flavouring agents – natural or artificial flavours (e.g., fruit flavour) to enhance taste acceptability
- Paraffin (liquid or light) – used as a coating agent to improve the flow properties of the granules and aid swallowing
- Talc – anti-caking agent
Always check the full list of excipients on the product packaging, particularly if you have known allergies or intolerances to specific food additives, sugars, or pharmaceutical excipients. Patients with rare hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should confirm the sugar content with their pharmacist before use.
Inolaxol granules are typically brown or brown-orange coated particles with a mild herbal or fruit-flavoured aroma. The granules have a slightly gritty texture and should be taken directly with water or mixed briefly into soft food. They should not be chewed extensively, as this may release an unpleasant taste and may reduce the controlled-release properties of the formulation.
Frequently Asked Questions About Inolaxol
Inolaxol is a combination bulk-forming and stimulant laxative used for the short-term treatment of constipation in adults and adolescents over 12 years. It contains sterculia (karaya gum), which absorbs water and increases stool bulk, and frangula bark, which gently stimulates bowel motility. It is available over the counter and is taken as granules with plenty of water.
Inolaxol typically produces a bowel movement within 8 to 24 hours. The bulk-forming component (sterculia) begins absorbing water relatively quickly, while the stimulant component (frangula bark) requires approximately 8–12 hours to reach and be activated in the colon. For this reason, many patients find taking Inolaxol in the evening results in a comfortable morning bowel movement.
Inolaxol can be taken daily for short-term relief, but the stimulant laxative component (frangula bark) should not be used continuously for more than one to two weeks without medical advice. Prolonged use of stimulant laxatives may lead to electrolyte imbalance (especially low potassium), dependency, and reduced natural bowel function. If you need a laxative for longer periods, consult your doctor about alternative options.
Inolaxol should be used with caution during pregnancy. The bulk-forming component (sterculia) is generally considered safe, but the stimulant component (frangula bark) contains anthraquinones that may theoretically stimulate uterine contractions. Pregnant women should consult their doctor or midwife before use. Pure bulk-forming laxatives (without stimulant) or osmotic laxatives (like lactulose) are usually preferred as first-line options during pregnancy.
Taking Inolaxol without adequate water is potentially dangerous. The sterculia component swells enormously when it absorbs water. If there is insufficient fluid in the gastrointestinal tract, the granules can swell and form a solid mass in the oesophagus or intestine, potentially causing choking or intestinal obstruction. Always take Inolaxol with at least a full glass of water (200–250 mL), remain upright for at least 30 minutes, and never take it immediately before lying down.
Yes, Inolaxol is an over-the-counter (OTC) medication available without a prescription in most countries where it is sold. It can be purchased directly from pharmacies. However, if constipation is persistent (more than two weeks), recurrent, or accompanied by alarm symptoms such as blood in the stool, unexplained weight loss, or severe abdominal pain, you should consult a doctor before self-treating.
References
- World Gastroenterology Organisation (WGO). WGO Global Guidelines: Constipation – A Global Perspective. WGO, 2023. Available at: worldgastroenterology.org/guidelines
- National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary: Constipation. NICE, 2024. Available at: cks.nice.org.uk
- Joint Formulary Committee. British National Formulary (BNF): Laxatives. London: BMJ Group and Pharmaceutical Press, 2025.
- American College of Gastroenterology (ACG). Chang L, et al. ACG Clinical Guideline: Management of Chronic Idiopathic Constipation. Am J Gastroenterol. 2021;116(4):818-835. doi:10.14309/ajg.0000000000001178
- European Medicines Agency (EMA). Committee on Herbal Medicinal Products (HMPC). Assessment Report on Rhamnus frangula L., cortex. EMA/HMPC, 2017.
- European Medicines Agency (EMA). Committee on Herbal Medicinal Products (HMPC). Assessment Report on Sterculia (Karaya gum). EMA/HMPC.
- Wald A, et al. ACG Clinical Guideline: Management of Benign Anorectal Disorders. Am J Gastroenterol. 2021;116(10):1987-2008.
- Tack J, et al. Diagnosis and treatment of chronic constipation – a European perspective. Neurogastroenterol Motil. 2011;23(8):697-710. doi:10.1111/j.1365-2982.2011.01709.x
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO, 2023.
- Portalatin M, Winstead N. Medical management of constipation. Clin Colon Rectal Surg. 2012;25(1):12-19. doi:10.1055/s-0032-1301754
Medical Editorial Team
This article was written and reviewed by our medical editorial team, consisting of licensed physicians with specialist qualifications in gastroenterology and clinical pharmacology.
Medical Content
iMedic Medical Editorial Team – Specialists in Gastroenterology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent review according to WHO, EMA, BNF, and ACG guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses, and international clinical guidelines (GRADE framework)
Last Updated
– Next scheduled review: August 2026
All medical content on iMedic is written according to the GRADE evidence framework and reviewed by board-certified physicians. We maintain strict editorial independence with no pharmaceutical company sponsorship or commercial funding. For more information about our editorial process, visit our editorial standards page.